[
    [
        {
            "time": "",
            "original_text": "混改中的紫鑫药业人参板块引质疑 总经理回复称将是强势增长的“蓄水池”",
            "features": {
                "keywords": [
                    "混改",
                    "紫鑫药业",
                    "人参板块",
                    "质疑",
                    "总经理",
                    "强势增长",
                    "蓄水池"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "混改中的紫鑫药业人参板块引质疑 总经理回复称将是强势增长的“蓄水池”",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]